| Patents for C07D 333 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom (32,883) |
|---|
| 01/29/2008 | US7323495 Synthetic lactone formulations and method of use |
| 01/29/2008 | CA2220999C Process for the hydrogenation of imines |
| 01/29/2008 | CA2142998C N-(alkanoylamino-2-hydroxypropyl)-sulfonamides useful as retroviral protease inhibitors |
| 01/29/2008 | CA2136120C Treatment of incontinence |
| 01/24/2008 | WO2008010481A1 Aminoindan derivative or salt thereof |
| 01/24/2008 | WO2008009914A1 Thiophenemethyl salicylate and related compounds as flavours and fragrances |
| 01/24/2008 | WO2008009881A1 Chemical compounds |
| 01/24/2008 | WO2007137103A3 Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
| 01/24/2008 | WO2007134168A3 Process for preparing duloxetine |
| 01/24/2008 | WO2007119114A3 Improved synthesis and preparations of duloxetine salts |
| 01/24/2008 | WO2007096707A3 Improved synthesis and preparations of duloxetine salts |
| 01/24/2008 | US20080021109 5-[3-(2,6-Dimethylbenzyloxy)-phenyl]-pent-4-enoic acid ethyl ester; insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis, arteriosclerosis; side effects reduction; orally active |
| 01/24/2008 | US20080021091 Crystalline duloxetine hydrochloride |
| 01/24/2008 | US20080021090 dissolving duloxetine in a first organic solvent (e.g.ethyl acetate) to form a first solution; adding the first solution to a second organic solvent (e.g.ethanol) comprising HCl to form a second solution;allowing duloxetine hydrochloride to crystallize out from second solution; collecting the product |
| 01/24/2008 | US20080021089 Crystalline duloxetine hydrochloride |
| 01/24/2008 | US20080021087 Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders |
| 01/24/2008 | CA2658376A1 4-heteroaryl-substituted 1-aminocyclohexane-1- and cyclohexane-1-derivatives having effects of the opioid receptor system |
| 01/23/2008 | EP1880720A1 Substituted acrylamide derivative and pharmaceutical composition comprising the same |
| 01/23/2008 | EP1880429A1 Polyacene and semiconductor formulation |
| 01/23/2008 | EP1879895A1 Enzyme inhibitors |
| 01/23/2008 | EP1879879A1 Compounds and methods for the treatment or prevention of flavivirus infections |
| 01/23/2008 | EP1879878A2 New heterocyclylethylcarboxamide derivatives |
| 01/23/2008 | EP1879877A2 Antimicrobial agents |
| 01/23/2008 | EP1879850A1 Acrylic ester compound and manufacturing intermediate thereof, method for manufacturing acrylic ester compound, and latent electrostatic image bearing member, image forming method, image forming apparatus and process cartridge |
| 01/23/2008 | EP1879849A1 Process for preparing memantine |
| 01/23/2008 | EP1556354B1 Therapeutic piperazine derivates useful for treating pain |
| 01/23/2008 | CN101108845A Novel method of producing strontium ranelate heptahydrate |
| 01/23/2008 | CN100363369C Laminated organic-inorganic perofskite with metal defect inorganic frame |
| 01/23/2008 | CN100363362C Thiazole derivatives as NPY receptor antagonists |
| 01/22/2008 | US7321044 Synthesis of oxygen-substituted benzocycloheptenes as valuable intermediate products for the production of tissue-selective estrogens |
| 01/22/2008 | US7321001 carboxylic acid derivatives which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer |
| 01/22/2008 | US7320983 Sulfur compounds such as phenylmethyl [2R-hydroxy-3-[(3-methylbutyl) (phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate, used for prevention of viral diseases and replication |
| 01/22/2008 | CA2392168C Vitamin d analogues |
| 01/22/2008 | CA2374362C Urea derivatives as hiv aspartyl protease inhibitors |
| 01/22/2008 | CA2374247C Heterocyclic derivatives useful as anticancer agents |
| 01/22/2008 | CA2226757C Alkylation process |
| 01/17/2008 | WO2008008701A2 Substituted cyclopentane derivatives as therapeutic agents |
| 01/17/2008 | WO2008008700A2 Substituted cyclopentane derivatives as therapeutic agents |
| 01/17/2008 | WO2008008660A2 Cyclopentane derivatives as antiglaucoma agents |
| 01/17/2008 | WO2008007578A1 Compound, acid generator, resist composition and method for forming resist pattern |
| 01/17/2008 | WO2008006626A1 Triphenyl modified 5-membered heterocycles and their use as anticancer and antiinflammatory agents |
| 01/17/2008 | WO2007080159A3 Pyridine-, isoxazole, thiophenecarboxamide compounds having activity at the glycine transporter glyt1 and uses thereof |
| 01/17/2008 | US20080015363 Process for the preparation of (S)-(-)-N,N-dimethyl-3-(2-thienyl)-3-hydroxypropananine, a duloxetine intermediate |
| 01/17/2008 | US20080015362 Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine |
| 01/17/2008 | US20080015352 zinc complexed with triiodothyronine; improved potency, stability, absorbability, targeted delivery |
| 01/17/2008 | US20080015253 Peroxisome Proliferator Activated Receptors modulators; ethyl (R,S)-2-(4-trifluoromethylphenyl)oxypent-4-enoate; dyslipidemia, atherosclerosis and diabetes |
| 01/17/2008 | US20080015242 Use of N-[3-[2-[2-(3-methylindazol-6-yloxy)ethylamino]-1-hydroxyethyl]phenyl]methanesulfonamide or salt for treating diabetes, obesity, hyperlipidemia and urinary incontinence; drug interaction side effect reduction |
| 01/17/2008 | US20080015231 Therapeutic compounds |
| 01/17/2008 | US20080015227 Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
| 01/17/2008 | US20080015219 Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted cyclopentanone or hydroxycyclopentane compounds |
| 01/17/2008 | US20080015216 Histone Deacetylase Inhibitors |
| 01/17/2008 | US20080015209 Compounds for the treatment of metabolic disorders |
| 01/17/2008 | CA2659121A1 Therapeutic compounds |
| 01/17/2008 | CA2657719A1 Cyclopentane derivatives as antiglaucoma agents |
| 01/17/2008 | CA2657625A1 Therapeutic compounds |
| 01/16/2008 | EP1877462A1 Semiconductors containing perfluoroether acyl oligothiophene compounds |
| 01/16/2008 | EP1877380A1 Sulfonylamino(thio)carbonyl compounds in the form of herbicides or plant growth regulators |
| 01/16/2008 | EP1877377A2 Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles |
| 01/16/2008 | EP1877366A1 Hydroxamic acid dervicatives as inhibitors of hdac enzymatic activity |
| 01/16/2008 | EP1687288B1 Substituted aryl cycloalkanol derivatives and methods of their use |
| 01/16/2008 | EP1644320B1 Indane derivates as muscarinic receptor agonists |
| 01/16/2008 | EP1458784B1 3,4-alkylenedioxythiophene compounds and polymers thereof |
| 01/16/2008 | EP1458684B1 Therapeutic heterocycles as bradykinin b2 receptor antagonists |
| 01/16/2008 | CN101107253A Mitotic kinesin inhibitors |
| 01/16/2008 | CN101107239A N-[(4, 5-diphenyl-3-alkyl-2-thienyl) methyl] amine (amide, sulfonamide, carbamate and urea) derivatives as cannabinoid CB1 receptor antagonists |
| 01/16/2008 | CN101107226A Phenoxyacetic acid derivatives useful for treating respiratory diseases |
| 01/16/2008 | CN101104614A Method of preparing (S)-dulouxetine key intermediate |
| 01/15/2008 | US7319163 N-[3,5-Dibromo-4-(3-bromobenzyloxy)benzoyl]benzenesulphonamide for example; cardiac arrhythmias, thyrotoxicosis and subclinical hyperthyroidism |
| 01/15/2008 | US7319152 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators |
| 01/15/2008 | US7319111 Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists |
| 01/15/2008 | US7319107 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| 01/15/2008 | CA2419934C Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same |
| 01/15/2008 | CA2265666C Cytostatic hydroxamic acid derivatives |
| 01/10/2008 | WO2008004191A2 Process for the preparation of enantiomerically pure salts of n-methyl-3- ( 1-naphthaleneoxy) -3- (2-thienyl) propanamine |
| 01/10/2008 | WO2008003378A1 Sulfamate benzothiophene derivatives |
| 01/10/2008 | WO2007137107A3 Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
| 01/10/2008 | WO2007136572A3 Antidiabetic bicyclic compounds |
| 01/10/2008 | WO2007135080A3 (2r)-2-[(4-sulfonyl)aminophenyl]propanamides and pharmaceutical compositions containing them |
| 01/10/2008 | US20080009640 Supported amorphous ni-b alloy catalyst, its preparation and use |
| 01/10/2008 | US20080009543 N-[[4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-thienyl]methyl]-2-propylpentanamide; cannabinoid CB1 receptor antagonists; drug abuse, drug dependency; psychological disorders; antidepressants; antiepileptic agents; cogntion activators; analgesics; eating disorders |
| 01/10/2008 | US20080009521 Aryl Piperidine Amides |
| 01/10/2008 | US20080006797 Photochromic compound and optical functional material |
| 01/10/2008 | CA2656627A1 Sulfamatobenzothiophene derivatives |
| 01/10/2008 | CA2656128A1 Process for the preparation of enantiomerically pure salts of n-methyl-3(1-naphthaleneoxy)-3-(2-thienyl)propanamine |
| 01/10/2008 | CA2656126A1 Polymorphic form of duloxetine hydrochloride |
| 01/09/2008 | EP1876177A2 Reactive mesogenic charge transport compounds |
| 01/09/2008 | EP1874755A2 Benzothiophene hydroxamic acid derivatives |
| 01/09/2008 | EP1874754A1 Pure duloxetine hydrochloride |
| 01/09/2008 | EP1874746A2 Novel histamine h3-receptor ligands and their therapeutic applications |
| 01/09/2008 | EP1874721A2 Glycine transport inhibitors |
| 01/09/2008 | EP1874295A1 Benzothiophene derivatives |
| 01/09/2008 | EP1874294A1 Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions |
| 01/09/2008 | EP1663936B1 Biaryloxymethylarene-carboxylic acids |
| 01/09/2008 | EP1583756B9 Thiophene carboxamides as inhibitors of the enzyme ikk-2 |
| 01/09/2008 | EP1239877B1 Composition comprising a tnf-alpha inhibitor and an integrin alphavbeta3 receptor antagonist |
| 01/09/2008 | EP1176956B1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| 01/09/2008 | CN101103012A Novel biaromatic compounds that modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof |
| 01/09/2008 | CN100360507C Inhibition of raf kinase using substituted heterocyclic ureas |
| 01/08/2008 | US7317034 Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine compounds |
| 01/08/2008 | US7317028 Antitumor agents; autoimmune disease; skin disorders; anticancer agents |